Literature DB >> 17577869

Treatment of diplopia.

Paul H Phillips1.   

Abstract

Binocular diplopia occurs from misalignment of the eyes. The fixation object is imaged onto the fovea of one eye and a nonfoveal region of the misaligned eye, creating diplopia. Treatment options include ocular occlusion, monovision optical correction, prism glasses, strabismus surgery, and chemodenervation. Ocular occlusion and monovision optical correction enable the patient to ignore the image from the misaligned eye. Prism glasses alter the light pathways so that the fixation object is imaged onto the fovea of both eyes, despite ocular misalignment. Strabismus surgery and chemodenervation attempt to restore ocular alignment. This article reviews the mechanisms and indications for each of these treatment options for patients with diplopia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17577869     DOI: 10.1055/s-2007-979680

Source DB:  PubMed          Journal:  Semin Neurol        ISSN: 0271-8235            Impact factor:   3.420


  3 in total

1.  Ocular late effects in childhood and adolescent cancer survivors: a report from the childhood cancer survivor study.

Authors:  Kimberly F Whelan; Kayla Stratton; Toana Kawashima; John W Waterbor; Robert P Castleberry; Marilyn Stovall; Charles A Sklar; Roger J Packer; Pauline Mitby; Candice L Aitken; Julie Blatt; Leslie L Robison; Ann C Mertens
Journal:  Pediatr Blood Cancer       Date:  2010-01       Impact factor: 3.167

2.  Torsional anomalous retinal correspondence effectively expands the visual field in hemianopia.

Authors:  Premnandhini Satgunam; Eli Peli
Journal:  Optom Vis Sci       Date:  2012-09       Impact factor: 1.973

3.  Efficacy of intraorbital electroacupuncture for diabetic abducens nerve palsy: study protocol for a prospective single-center randomized controlled trial.

Authors:  Ling-Yun Zhou; Xue-Mei Li; Tie-Juan Liu; Xiao-Jie Ji; Ming Zhao; Chang Su; Ji-Chao Liu; Jiang-Yun Sun
Journal:  Neural Regen Res       Date:  2017-05       Impact factor: 5.135

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.